EUVIMEDEUVIMED entdecken
Crossref

QHHP Ameliorates MASH Through Modulation of a Cyp4a32–PPARγ–CD36‐Associated Lipotoxic Axis

Feixiang Xiong iD, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Juqiang Han, Yixin Hou

The FASEB Journal · 31.10.2026 · 40 (20)

DOI: 10.1096/fj.202600169r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 15.10.2026. Verfasst von Feixiang Xiong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: PPAR gamma, CD36 Antigens, Fatty Liver, Drugs, Chinese Herbal. Die Arbeit nennt 29 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Beijing Municipal Adminstration of Hospitals Incubating Program, High-Level Public Health Talent Development Program (Discipline Backbone-03-07).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatohepatitis (MASH) is a progressive stage of metabolic dysfunction‐associated fatty liver disease, for which effective pharmacological therapies remain limited. Qinggan Huatan Huoxue Prescription (QHHP) has been used clinically in the management of fatty liver disease and related metabolic disorders, but its overall efficacy and underlying mechanisms remain unclear. In this study, the therapeutic effects of QHHP on MASH were evaluated through clinical observation, animal experiments, cellular studies, multi‐omics analysis, and computational simulation. QHHP treatment was associated with improved liver function and selected lipid parameters in patients with MASH, attenuated steatosis, inflammation, and fibrosis in HFHC‐ and MCD‐induced mouse models, and reduced PA/OA‐induced lipid droplet accumulation in AML12 cells and PMHs. Transcriptomic and pathway analyses indicated the involvement of PPAR signaling and fatty acid metabolism‐related pathways. In vivo and in vitro findings showed that QHHP intervention was accompanied by downregulation of Cyp4a32, PPARγ, and CD36. Pathway‐intervention experiments further showed that siPPARγ enhanced, whereas Rosiglitazone partially reversed the inhibitory effects of QHHP on lipid droplet accumulation and related molecular expression, suggesting that PPARγ‐related lipid uptake signaling participates in its anti‐lipotoxic mechanism. QHHP may alleviate hepatic lipotoxic injury through multi‐component regulation of a lipid metabolism‐related network involving Cyp4a32, PPARγ, and CD36.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR gammaCD36 AntigensFatty LiverDrugs, Chinese HerbalCytochrome P450 Family 4AnimalsMiceHumansMaleMice, Inbred C57BLLipid MetabolismSignal TransductionLiver

Stichwörter der Autor:innen

Cyp4a32–PPARγ–CD36 axisPPARγ signaling pathwayQinggan Huatan Huoxue Prescriptionhepatic steatosismetabolic dysfunction‐associated steatohepatitis

Substanzen

PPAR gammaCD36 AntigensDrugs, Chinese HerbalCytochrome P450 Family 4Cd36 protein, mouse

Autor:innen und Institutionen

  • Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Institute of Infectious Diseases, Beijing, China.
  • National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Beijing Key Laboratory of Viral Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Department of Ambulatory Medicine, The Seventh Medical Center of PLA General Hospital, Beijing, China.

ORCID-Profile: Feixiang Xiong

Förderung

  • National Key Research and Development Program of China
  • Beijing Municipal Adminstration of Hospitals Incubating Program
  • High-Level Public Health Talent Development Program (Discipline Backbone-03-07)
  • Laboratory for Clinical Medicine, Capital Medical University

Zitieren

APA

Xiong, F., Yan, F., Jiang, Y., Ji, X., Wu, T., Zhou, Y., Zhang, X., Chen, D., Han, J., & Hou, Y. (2026). QHHP Ameliorates MASH Through Modulation of a Cyp4a32–PPARγ–CD36‐Associated Lipotoxic Axis. The FASEB Journal, 40(20). https://doi.org/10.1096/fj.202600169r

Vancouver

Xiong F, Yan F, Jiang Y, Ji X, Wu T, Zhou Y, et al. QHHP Ameliorates MASH Through Modulation of a Cyp4a32–PPARγ–CD36‐Associated Lipotoxic Axis. The FASEB Journal. 2026;40(20). doi:10.1096/fj.202600169r

BibTeX
@article{Xiong2026,
  author = {Xiong, Feixiang and Yan, Fengna and Jiang, Yuyong and Ji, Xiaomin and Wu, Tong and Zhou, Yang and Zhang, Xuejie and Chen, Dandan and Han, Juqiang and Hou, Yixin},
  title = {QHHP Ameliorates MASH Through Modulation of a Cyp4a32–PPARγ–CD36‐Associated Lipotoxic Axis},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {20},
  doi = {10.1096/fj.202600169r}
}
Kostenlos starten →